

FOUNDATION BACKGROUNDER

The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization funding and accelerating prostate cancer research. Every

3 minutes a man is diagnosed with prostate cancer, and millions of men and their families are fighting the disease globally. In the United States, prostate cancer affects 1 in 9 men, making it the



most common non-skin cancer in America. This means that a non-smoking man is more likely to develop prostate cancer than he is to develop colon, bladder, melanoma, lymphoma, and kidney cancers combined. In 2020 alone, it is estimated that nearly 192,000 men will be diagnosed with prostate cancer, and more than 33,000 will die from the disease. An African American man is 76% more likely to develop prostate cancer than a Caucasian man, and more than twice as likely to die from the disease.

For 27 years, PCF has demonstrated a firm commitment to saving lives and finding a cure for prostate cancer.

We have raised more than \$800 million and provided funding to more than 2,200 research projects at more than 220 cancer centers and universities in 22 countries around the world. Each year at PCF, 84 cents of every dollar spent goes directly towards prostate cancer research. In 2019, these funds resulted in 23 chemically distinct, "first-in-field" anti-prostate cancer medicines in the pipeline, 14 team science awards supporting 132 individual investigators, and 41 early-career scientists funded. This research is pivotal to the development of new, life-extending therapies that will improve survivorship and quality of life for all men with prostate cancer.

PCF is unique in its innovative approach to medical research funding. PCF identifies the most promising research ideas and attracts brilliant individuals and teams of scientists early in their careers to PCF's Global Research Enterprise. By channeling resources directly to the world's top scientific minds, PCF is able to cut through red tape, speed scientific breakthroughs and deliver new treatments to patients. PCF funds a variety of different kinds of projects that vary in focus, scope and duration. PCF Challenge Awards fund teams of scientists working on critical unmet needs for advanced prostate cancer. PCF Creativity Awards support exceptionally novel projects to produce scientific breakthroughs. PCF Young Investigator Awards jumpstart research programs for early-career scientists and researchers. PCF researchers connect globally to exchange information and share scientific data in real time.

Since inception, PCF has been a pioneer in new drug development, providing key funding for FDA-approved treatments that improve survivorship. Having recruited more than 5,000 of the best physician-scientists worldwide, many of the most important discoveries in the fight against prostate cancer since 1993 have resulted from PCF funding or coordination. Thanks in large part to the work of PCF-funded researchers, the number of drugs approved to treat prostate cancer doubled – from just 6 drugs approved in nearly 30 years to another 10 drugs approved in the last 10 years. Of those 10 drugs, 9 were FDA-approved because they actually prolong patients' lives, rather than simply ease their symptoms. As of early 2020, there are now a total of 21 drugs approved by the FDA for treatment of prostate cancer, with even more in the pipeline.

By funding leading-edge research with innovative treatments now reaching patients, PCF has helped reduce the U.S. death rate from prostate cancer by 52%. Without a doubt, the prognosis for men diagnosed with prostate cancer has never been more encouraging. Recent advances enable men with prostate cancer to live longer, more productive lives, and when detected early through routine physical exams and minimally invasive blood tests, prostate cancer is 100% treatable. Nearly 100% of men diagnosed with prostate cancer in the local or regional stages will be disease free after 5 years. Equally important is the fact that 4 discoveries in prostate cancer now extend to saving lives in more than 18 other forms of cancer, including breast, myeloma, colon, lung, ovarian, melanoma, pediatric neuroblastoma, bladder, and thyroid cancers. Because precision medicine targets genes and not organs, these same therapies that help men with metastatic prostate cancer have been shown to be effective in more than 73 other forms of human cancer.

By connecting patients, loved ones, care providers, and scientists to critical updates, new developments, best practices, and the latest news from the treatment pipeline, PCF provides hope for men diagnosed with prostate cancer. PCF is dedicated to keeping the pace of scientific progress moving rapidly to ensure new discoveries for years to come. Eliminating prostate cancer in our lifetimes is a possibility within reach, and the day when the disease becomes a manageable condition is closer than ever. PCF has become the model for other disease-research organizations and with your support, we will find a cure. Curing together, we can change the future.

For more information, please go to pcf.org.





Prostate Cancer Foundation Curing Together.

1250 Fourth Street, Santa Monica, CA 90401 / Tel 310.570.4700 Fax 310.570 4701 | www.pcf.org